摘要
目的:观察罗红霉素对慢性阻塞性肺疾病(COPD)稳定期患者气道炎症的疗效,为COPD稳定期治疗提供依据。方法:COPD稳定期门诊患者46例分为观察组和对照组。对照组给予常规治疗,观察组在对照组基础上加用罗红霉素软胶囊150 mg·d-1,均治疗10个月。比较两组患者痰液和血清中γ-IFN、IL-8和TNF-α等细胞因子水平,以及痰液中白细胞、中性粒细胞计数的变化,观察两组药品不良反应发生情况。结果:用药5个月时,观察组患者血清和痰液中的γ-IFN、IL-8和TNF-α等细胞因子水平均较用药前明显下降(P<0.05),痰中白细胞、中性粒细胞计数较用药前明显下降(P<0.05),且上述指标均明显低于对照组(P<0.05);用药10个月时,观察组患者上述指标较用药5个月时又有明显下降(P<0.05),且均显著低于对照组(P<0.05)。观察组仅发生1例药品不良反应,患者退出研究。结论:长期服用小剂量罗红霉素可以降低COPD稳定期患者痰液和血清中的细胞因子,以及痰液中炎症细胞计数,对气道炎症有一定的抑制作用。
Objective:To investigate the effect of roxithromycin on airway inflammation in chronic obstructive pulmonary disease ( COPD) patients at stable phase to provide evidence for the clinical diagnosis and treatment .Methods:Totally 46 cases of outpatients with stable COPD were divided into the observation group and the control group .The control group received the conventional treatment , while the observation group was treated with roxithromycin capsules 150mg.d-1 additionally, and the treatment course was 10 months. The sputum, serum cytokines γ-IFN, IL-8 and TNF-αlevels, sputum leukocyte , neutrophil count and adverse reactions were observed and compared between the groups .Results:After the 5-month treatment, the levels of γ-IFN, IL-8 and TNF-αcytokines in serum and sputum in the observation group were significantly lower than those before the treatment (P〈0.05) and in the control group (P〈0.05).After the 10-month treatment, the above indices in the observation were further decreased when compared with those after the 5-month treatment (P〈0.05), which were notably lower than those in the control group (P〈0.05).There was only one case of ad-verse drug reactions in the observation group , and the patient was out of the study .Conclusion:Long-term use of roxithromycin at low dose can reduce cytokines in serum and sputum and inflammatory cell count in sputum in stable COPD patients , which exhibits the effect on airway inflammation to some extent .
出处
《中国药师》
CAS
2016年第7期1334-1336,共3页
China Pharmacist
关键词
罗红霉素
慢性阻塞性肺疾病
稳定期
气道炎症
细胞因子
炎症细胞
Roxithromycin
Chronic obstructive pulmonary disease
Stable phase
Airway inflammation
Cytokines
Inflammatory cells